Skip to content
MarketScale
‹ Back to IndustriesSciences

The Differences Between Calendered and Extruded Vinyl Films

There are two main ways to produce vinyl films: calendering and extrusion. Each of these industrial processes can be used to produce a range of film and sheet products with distinct qualities. As with any manufacturing process, there are advantages and disadvantages to each approach. What is Calendering? In calendering, raw materials enter a mixing…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Promoted Content · Promoted Content
Share
The Differences Between Calendered and Extruded Vinyl Films

Key takeaways

01

There are two main ways to produce vinyl films: calendering and extrusion.

02

Each of these industrial processes can be used to produce a range of film and sheet products with distinct qualities.

03

As with any manufacturing process, there are advantages and disadvantages to each approach.

There are two main ways to produce vinyl films: calendering and extrusion. Each of these industrial processes can be used to produce a range of film and sheet products with distinct qualities. As with any manufacturing process, there are advantages and disadvantages to each approach.

What is Calendering?

In calendering, raw materials enter a mixing chamber where they are melted. This molten plastic then moves through a series of heated rollers that compress the material to the desired thickness. Finally, it passes through a series of surface conditioning and cooling rolls, then is wound into custom rolls or cut into sheets.

Calendering Pros and Cons

On the plus side, calendering allows high run rates on films 6 to 60 mils thick. Calendered material typically has higher tensile properties, product uniformity, and unusually close gauge control when compared with extruded films. The added mixing in the process is ideal for highly filled applications and materials, and has the additional advantage that melt degassing occurs in the process. Finally, materials with lower melt temperatures can be used in calendering due to the high pressures used between rollers.

On the downside, calendered products may have issues with pinholes at gauges less than 6 mils, and there may be appearance issues. The rollers used may create surface blemishes and edge buildup on the melt path can create black specs. Also, the sheets are usually less glossy than extruded materials. Calendering is a process that is typically not economically profitable for short production runs.

What is Extrusion?

In extrusion, mixed plastic compound is conveyed through a heated barrel using a spiral shaped screw, converting it into molten plastic. A lip die flattens the mass into a sheet of the desired width and thickness, which then passes through heated embossing rolls that impart a surface finish. The sheet is then trimmed to its final dimension.

Extrusion Pros and Cons

Extrusion offers a number of advantages. Even at thinner gauges, extruded film is pinhole free and has improved “lay flat” qualities. The extrusion process is more flexible, allowing faster changeovers for smaller production runs. The process also delivers better dimensional stability in both machine and cross web directions, and screws can be designed for specific formulations to help improve film characteristics. Finally, the streamlined melt flow reduces black specks.

A disadvantage of extrusion is the requirement for higher melt temperatures. There can also be poor mixing on highly filled formulations. Finally, melt degassing can be a production issue.

Presco Uses Extrusion to Produce Its Presco Engineered Film

Presco compounds and extrudes the flexible vinyl film known as Presco Engineered Film, which is custom formulated to the exact specification of our customers. And in 2017, Presco added Ethylene Vinyl Acetate (EVA) film extrusion to its capabilities as an option for PVC-free manufacturing. To learn about our capabilities, click here.

About the author

PC
Promoted Content

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

PC
Promoted Content

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512